Net sales remained stable at SEK 17.5m in 2025, with improved results and strong recurring revenue growth. Capital raises secured liquidity, and the company maintains a leading global market position with no direct clinical competitors.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.